Lilly’s Cassell joins PhRMA bioterror team
Lilly VP-Scientific Affairs Gail Cassell, PhD, joins the Pharmaceutical Research & Manufacturers of America on "part-time basis to work on the industry's biomedical preparedness issues." Cassell will "help to develop a long-term strategy for research on infectious diseases"...
You may also be interested in...
HHS would retain authority over drug research related to bioterrorism under the House Energy & Commerce Committee mark of the "Homeland Security Act" (HR 5005) completed July 11
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.